Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i)

Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) are medications that help manage type 2 diabetes by preventing the kidneys from reabsorbing glucose back into the bloodstream. Instead, they cause excess sugar to be eliminated through urine, which lowers blood sugar levels. Beyond controlling glucose, SGLT2 inhibitors also offer benefits like reducing blood pressure, decreasing the risk of heart failure, and protecting kidney function. They are an effective part of a comprehensive approach to diabetes treatment, improving overall health outcomes.